NMTC
NeuroOne Medical Technologies Corporation
NMTC has the edge over NVO overall, supported by stronger modeled upside and stronger fundamentals.
NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
NMTC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
NMTC's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
NMTC PE Valuation
NMTC has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
NMTC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
NMTC has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
NMTC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.04 | -$0.14 |
| Q1 2026 | -$0.94 | +$0.38 |
| Q4 2025 | -$1.08 | +$0.48 |
| Q3 2025 | -$0.54 | +$2.22 |
| Q2 2025 | -$0.90 | +$1.98 |
| Q1 2025 | -$1.32 | +$2.16 |
| Q4 2024 | -$1.56 | +$2.52 |
| Q3 2024 | -$2.76 | +$1.14 |
NMTC is still losing money, but far less than before: $1.04 per share over the past year, against $17.46 at its worst in mid-2020.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over NMTC on earnings quality, reporting a profit while its opponent remains loss making.
NMTC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $2M | +16% |
| Q1 2026 | $1.9M | +34% |
| Q4 2025 | $2.9M | -12% |
| Q3 2025 | $2.7M | +907% |
| Q2 2025 | $1.7M | +105% |
| Q1 2025 | $1.4M | +0.7% |
| Q4 2024 | $3.3M | +235% |
| Q3 2024 | $272.3K | -63% |
NMTC's revenue is recovering but still below its 2024 peak: $2M last quarter, up 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -123% | -12 points |
| Q1 2026 | -129% | +65 points |
| Q4 2025 | -59% | -111 points |
| Q3 2025 | -50% | +985 points |
| Q2 2025 | -111% | +227 points |
| Q1 2025 | -193% | +16 points |
| Q4 2024 | 52% | +399 points |
| Q3 2024 | -1034% | -608 points |
NMTC's operating margin was −123% last quarter, down 12 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over NMTC on profitability, with a higher operating margin.
NMTC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$1.4M | -$1.3M |
| Q4 2025 | -$3.2M | -1617% |
| Q3 2025 | -$1.5M | +$1.2M |
| Q1 2025 | -$56.1K | +$2.2M |
| Q4 2024 | $208K | +$4.1M |
| Q3 2024 | -$2.7M | +$256.7K |
| Q2 2024 | -$2.4M | +$704.3K |
| Q1 2024 | -$2.2M | +$1.5M |
NMTC has the stronger cash trend. Its trailing FCF is up 8.9% versus its history, compared with NVO at down 14%.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
NMTC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3% | +255K shares |
| 1 year | +69% | +3.6M shares |
| 3 years | +223% | +6M shares |
| 5 years | +868% | +7.8M shares |
| Available history | +1227% | +8.1M shares |
NMTC has 9M diluted shares, up 69% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over NMTC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
NMTC Net Leverage
NMTC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
NMTC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 21.9 | Oversold |
| Stochastic | 3.3 | Oversold |
NMTC's weekly RSI is 22 (oversold) and its Stochastic is 3 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
NMTC PE vs Healthcare Sector
NMTC has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NMTC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.00 | 25% below |
| 20 week MA | $1.59 | 53% below |
| 50 week MA | $3.28 | 77% below |
| 100 week MA | $4.09 | 82% below |
| 200 week MA | $5.51 | 86% below |
NMTC is in a downtrend: it's below all five of its weekly moving averages, and 86% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over NMTC on trend strength, trading above more of its moving averages.
NMTC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.7 | $27.5 | -32% |
| 2021 | $27.5 | $13.2 | -52% |
| 2022 | $13.2 | $9.24 | -30% |
| 2023 | $9.24 | $9.48 | +2.6% |
| 2024 | $9.48 | $4.91 | -48% |
| 2025 | $4.91 | $4.38 | -11% |
| 2026 YTD | $4.38 | $0.75 | -83% |
NMTC has finished lower in five of the last six years. It's down 83% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over NMTC on returns for 2026, with the stronger performance.